Developer docs
API playgroundTry for free, no card

Search company profiles

BlueWhale Bio

Full company profile

uuid0000qkj

Namestring
BlueWhale Bio
Legal namestring
BlueWhale Bio, Inc.
Websiteurl
bluewhale.bio
Company typeenum
Private
Founded yearint
2023
Descriptiontext

BlueWhale Bio, Inc. is a Philadelphia-based biotechnology company spun out of the University of Pennsylvania in September 2023 that develops and sells cell-derived nanoparticle (CDNP) reagents under the Synecta platform for immune cell activation and expansion in cell and gene therapy manufacturing. The company's core products — Synecta T1, Synecta T2, and Synecta Modular — are engineered vesicles produced from mammalian cell lines that present defined combinations of stimulatory signals (e.g., OKT3 scFV), co-stimulatory ligands (CD86, 4-1BBL), and membrane-bound cytokines (IL-15RA/IL-15, IL-7) to drive T-cell activation in CAR-T workflows. The technology is licensed from co-founders Carl June and James Riley of Penn's Perelman School of Medicine, both globally recognized immunotherapy pioneers. Synecta is positioned to replace conventional bead-based activation methods, enabling Day 0 lentiviral transduction, eliminating bead-removal steps, and shortening manufacturing cycles (claims include a 3-day process versus longer conventional approaches).

The company monetizes primarily through direct sales of research-use CDNPs to cell therapy developers and academic medical centers, with quote-based pricing (net 30 terms) per the website Terms and Conditions. Go-to-market is enterprise field sales supplemented by conference presence (Cell & Gene Meeting on the Mesa, ISCT, AACR, IO360, SITC) and webinars. A strategic partnership with Avantor (announced October 2025) extends distribution into GMP-grade manufacturing scale for commercial cell therapy production. The company has secured an FDA Advanced Manufacturing Technology (AMT) designation (November 2025) and an accepted Drug Master File for Synecta T1, and achieved first-patient dosing in a University of Pennsylvania clinical trial (NCT04684563) in September 2025. As of the latest data, BlueWhale Bio had raised $18 million in seed financing led by Danaher Ventures with participation from Novalis LifeSciences and Marshall Wace, and disclosed a $15 million exempt securities offering (with $5 million sold) in 2025, while operating with 11-50 employees.

Short descriptiontext

BlueWhale Bio is a Philadelphia-based biotechnology company spun out of the University of Pennsylvania that develops Synecta cell-derived nanoparticles (CDNPs) for T-cell activation and expansion in CAR-T cell therapy manufacturing. It sells research-use reagents directly to cell therapy developers, with GMP-grade scale-up supported through an Avantor partnership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, CAR-T activation reagents, cell-derived nanoparticles, bioprocessing reagents, immune cell expansion
Industry3 codes
PRIMARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy Manufacturing Reagents
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Synecta Product Sales
TypeOne Time License
Description

Sale of Synecta T1, T2, and Modular CDNP products for research use in cell therapy development. Products are sold directly through the company's website and via direct sales to cell therapy manufacturers and academic researchers.

bluewhale.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Synecta™
Description

Cell-derived nanoparticle (CDNP) platform for immune cell activation and expansion in cell therapy manufacturing

bluewhale.bio
+3 more records
Core offering1 text field

BlueWhale Bio manufactures and sells the Synecta™ platform of cell-derived nanoparticles (CDNPs) used to activate and expand T cells during CAR-T and other immune cell therapy manufacturing. The CDNPs are engineered vesicles produced from mammalian cell lines that present defined combinations of activation signals, co-stimulatory ligands, membrane-bound cytokines, and adhesion molecules to mimic natural immune cell stimulation, eliminating bead-removal steps and enabling 3-day manufacturing with Day 0 lentiviral transduction. Customers are cell therapy developers, biomanufacturers, and academic medical centers, supported through direct sales, an e-commerce storefront, and a strategic GMP manufacturing partnership with Avantor.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Up to 30% of samples fail to reach target dose due to suboptimal activation
+2 more records
Product overview1 text field

BlueWhale Bio offers the Synecta™ platform for cell therapy manufacturing, comprising cell-derived nanoparticle (CDNP) products for immune cell activation and expansion. The core products include Synecta™ T1 (contains activation signals, co-stimulatory ligands, and membrane-bound cytokines), Synecta™ T2 (flexible platform with cytokine addition freedom), and Synecta™ Modular (customizable CDNP development service). The platform is designed for CAR-T cell manufacturing workflows, enabling Day 0 lentiviral transduction and 3-day manufacturing processes. Regulatory support offerings include Drug Master File (DMF) for clinical trials and FDA Advanced Manufacturing Technology (AMT) designation. All products are for research use only.

Product and service5 records
1Synecta™ T1
CategoryCell Therapy Activation and Expansion Reagent
Description

Cell-derived nanoparticles (CDNPs) for T cell activation and expansion in CAR-T manufacturing. Contains membrane-bound activation signal (OKT3 scFV), co-stimulatory ligands (CD86, 4-1BBL), and membrane-bound cytokines (IL-15RA/IL-15, IL-7) to mimic natural T-cell stimulation and enable activation without addition of soluble cytokines. Enables Day 0 lentiviral transduction, improved cell yields, and faster expansion for cell therapy developers and manufacturers.

2Synecta™ T2
CategoryCell Therapy Activation and Expansion Reagent
Description

Cell-derived nanoparticles for T cell activation and expansion providing maximal freedom to add cytokines. Contains OKT3 scFV activation signal and CD86 co-stimulatory ligand, designed for easy and robust activation with high dose-dependent cell yields. Requires no de-beading step and offers a simplified workflow for cell therapy developers and manufacturers.

3Synecta™ Modular
CategoryCustom CDNP Development Service
Description

Customizable CDNP development service that lets clients design cell-derived nanoparticles with specific transmembrane signals using BlueWhale Bio's modular cell line library. Enables Day 0 transduction, addition of any soluble or membrane-bound cytokines, and use with any bioreactor without protocol adjustments. Projects typically take 6-9 months with collaborative research planning for cell therapy developers seeking tailored activation reagents.

4Drug Master File (DMF) for Synecta T1
CategoryRegulatory Support Service
Description

Regulatory support offering that allows clinical-stage cell therapy developers to reference BlueWhale Bio's FDA-accepted Drug Master File for Synecta T1 in their new or amended IND submissions, supporting use of Synecta T1 CDNPs in clinical CAR-T manufacturing without requiring customers to compile and submit their own manufacturing CMC filings.

5FDA Advanced Manufacturing Technology (AMT) Designation for Synecta Platform
CategoryRegulatory Support Service
Description

Regulatory designation service for the Synecta platform that signals FDA confidence in the scalability of the CDNP manufacturing approach, enables early FDA engagement on platform improvements, and supports customers pursuing commercial-scale cell therapy manufacturing.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-15
Description

Strategic partnership to accelerate CAR-T manufacturing by scaling up production of BlueWhale's Synecta CDNP platform. The collaboration aims to reduce manufacturing time and costs while expanding patient access. Avantor brings bioprocessing and GMP-grade custom ancillary-reagent manufacturing capabilities to produce GMP-grade CDNP materials.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Miltenyi Biotec is the dominant supplier of T-cell activation and expansion reagents (including T Cell TransAct nanomatrix) used in CAR-T manufacturing workflows globally. Direct competitor to BlueWhale's Synecta platform in the cell therapy activation reagent market.

TypeBroad incumbent
Description

Thermo Fisher's Gibco CTS product line includes Dynabeads CD3/CD28 activation reagents and a broad portfolio of cell therapy manufacturing consumables and instruments. A large incumbent whose cell therapy franchise directly overlaps with BlueWhale's target market.

TypeDirect peer
Description

Bio-Techne supplies GMP-grade cytokines (IL-2, IL-7, IL-15) and activation reagents widely used in CAR-T and other cell therapy manufacturing. Competes with the soluble-cytokine-free value proposition of Synecta T1.

TypeDirect peer
Description

CellGenix is a specialized supplier of GMP-manufactured raw materials and ancillary reagents for cell and gene therapy, including cytokines, media, and activation reagents. Closely comparable niche player focused on cell therapy manufacturing inputs.

TypeEmerging player
Description

MaxCyte provides electroporation-based cell engineering technology used in cell therapy manufacturing, including partnerships with major CAR-T developers. Adjacent technology provider in the cell therapy manufacturing workflow that competes for similar customer relationships.

TypeEmerging player
Description

Ori Biotech develops a fully closed, automated cell and gene therapy manufacturing platform. BlueWhale has co-hosted educational webinars with Ori, suggesting overlapping but not directly competing offerings in next-generation CAR-T manufacturing.

TypeBroad incumbent
Description

Cytiva (a Danaher company) supplies a broad portfolio of cell therapy bioprocessing tools, media, and instruments. Synergistic with BlueWhale's positioning - BlueWhale's lead investor Danaher also owns Cytiva - and represents both a partnership opportunity and a potential future competitive threat at the platform level.

TypeBroad incumbent
Description

Lonza is one of the world's largest cell and gene therapy CDMOs and also supplies process development tools and ancillary materials. A broad incumbent in the cell therapy manufacturing value chain that competes for ancillary reagent spend with cell therapy developers.

TypeBroad incumbent
Description

Charles River Laboratories operates a major cell and gene therapy CDMO business and supplies ancillary manufacturing materials. A scaled incumbent competing for the same customer wallet in cell therapy development and manufacturing services.

TypeEmerging player
Description

Kytopen is an MIT spinout developing continuous flow electroporation technology for cell engineering, including CAR-T manufacturing. BlueWhale announced a partnership with Kytopen in September 2025, indicating complementary rather than directly competing technology positions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BlueWhale Bio

Cell Therapy Manufacturing Reagentsbluewhale.bio

BlueWhale Bio is a Philadelphia-based biotechnology company spun out of the University of Pennsylvania that develops Synecta cell-derived nanoparticles (CDNPs) for T-cell activation and expansion in CAR-T cell therapy manufacturing. It sells research-use reagents directly to cell therapy developers, with GMP-grade scale-up supported through an Avantor partnership.

What BlueWhale Bio does

BlueWhale Bio, Inc. is a Philadelphia-based biotechnology company spun out of the University of Pennsylvania in September 2023 that develops and sells cell-derived nanoparticle (CDNP) reagents under the Synecta platform for immune cell activation and expansion in cell and gene therapy manufacturing. The company's core products — Synecta T1, Synecta T2, and Synecta Modular — are engineered vesicles produced from mammalian cell lines that present defined combinations of stimulatory signals (e.g., OKT3 scFV), co-stimulatory ligands (CD86, 4-1BBL), and membrane-bound cytokines (IL-15RA/IL-15, IL-7) to drive T-cell activation in CAR-T workflows. The technology is licensed from co-founders Carl June and James Riley of Penn's Perelman School of Medicine, both globally recognized immunotherapy pioneers. Synecta is positioned to replace conventional bead-based activation methods, enabling Day 0 lentiviral transduction, eliminating bead-removal steps, and shortening manufacturing cycles (claims include a 3-day process versus longer conventional approaches).

The company monetizes primarily through direct sales of research-use CDNPs to cell therapy developers and academic medical centers, with quote-based pricing (net 30 terms) per the website Terms and Conditions. Go-to-market is enterprise field sales supplemented by conference presence (Cell & Gene Meeting on the Mesa, ISCT, AACR, IO360, SITC) and webinars. A strategic partnership with Avantor (announced October 2025) extends distribution into GMP-grade manufacturing scale for commercial cell therapy production. The company has secured an FDA Advanced Manufacturing Technology (AMT) designation (November 2025) and an accepted Drug Master File for Synecta T1, and achieved first-patient dosing in a University of Pennsylvania clinical trial (NCT04684563) in September 2025. As of the latest data, BlueWhale Bio had raised $18 million in seed financing led by Danaher Ventures with participation from Novalis LifeSciences and Marshall Wace, and disclosed a $15 million exempt securities offering (with $5 million sold) in 2025, while operating with 11-50 employees.

BlueWhale Bio firmographics

Firmographics
Name
BlueWhale Bio
Legal name
BlueWhale Bio, Inc.
Website
https://bluewhale.bio
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
BlueWhale Bio is a Philadelphia-based biotechnology company spun out of the University of Pennsylvania that develops Synecta cell-derived nanoparticles (CDNPs) for T-cell activation and expansion in CAR-T cell therapy manufacturing. It sells research-use reagents directly to cell therapy developers, with GMP-grade scale-up supported through an Avantor partnership.
Ownership category
akta.pro rank

BlueWhale Bio industry classification

Industry
Product category
Cell Therapy Manufacturing Reagents
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)

Keywords

  • Cell therapy manufacturing
  • CAR-T activation reagents
  • Cell-derived nanoparticles
  • Bioprocessing reagents
  • Immune cell expansion

Where BlueWhale Bio is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BlueWhale Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Synecta Product Sales: Sale of Synecta T1, T2, and Modular CDNP products for research use in cell therapy development. Products are sold directly through the company's website and via direct sales to cell therapy manufacturers and academic researchers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

BlueWhale Bio product offering

Product offering

Core offering

BlueWhale Bio manufactures and sells the Synecta™ platform of cell-derived nanoparticles (CDNPs) used to activate and expand T cells during CAR-T and other immune cell therapy manufacturing. The CDNPs are engineered vesicles produced from mammalian cell lines that present defined combinations of activation signals, co-stimulatory ligands, membrane-bound cytokines, and adhesion molecules to mimic natural immune cell stimulation, eliminating bead-removal steps and enabling 3-day manufacturing with Day 0 lentiviral transduction. Customers are cell therapy developers, biomanufacturers, and academic medical centers, supported through direct sales, an e-commerce storefront, and a strategic GMP manufacturing partnership with Avantor.

Product overview

BlueWhale Bio offers the Synecta™ platform for cell therapy manufacturing, comprising cell-derived nanoparticle (CDNP) products for immune cell activation and expansion. The core products include Synecta™ T1 (contains activation signals, co-stimulatory ligands, and membrane-bound cytokines), Synecta™ T2 (flexible platform with cytokine addition freedom), and Synecta™ Modular (customizable CDNP development service). The platform is designed for CAR-T cell manufacturing workflows, enabling Day 0 lentiviral transduction and 3-day manufacturing processes. Regulatory support offerings include Drug Master File (DMF) for clinical trials and FDA Advanced Manufacturing Technology (AMT) designation. All products are for research use only.

Differentiator

Problem solved

Functional benefit

Brands

  • Synecta™: Cell-derived nanoparticle (CDNP) platform for immune cell activation and expansion in cell therapy manufacturing
  • Synecta™ T1
  • Synecta™ T2
  • Synecta™ Modular

Products and services

  • Synecta™ T1 Cell-derived nanoparticles (CDNPs) for T cell activation and expansion in CAR-T manufacturing. Contains membrane-bound activation signal (OKT3 scFV), co-stimulatory ligands (CD86, 4-1BBL), and membrane-bound cytokines (IL-15RA/IL-15, IL-7) to mimic natural T-cell stimulation and enable activation without addition of soluble cytokines. Enables Day 0 lentiviral transduction, improved cell yields, and faster expansion for cell therapy developers and manufacturers.
  • Synecta™ T2 Cell-derived nanoparticles for T cell activation and expansion providing maximal freedom to add cytokines. Contains OKT3 scFV activation signal and CD86 co-stimulatory ligand, designed for easy and robust activation with high dose-dependent cell yields. Requires no de-beading step and offers a simplified workflow for cell therapy developers and manufacturers.
  • Synecta™ Modular Customizable CDNP development service that lets clients design cell-derived nanoparticles with specific transmembrane signals using BlueWhale Bio's modular cell line library. Enables Day 0 transduction, addition of any soluble or membrane-bound cytokines, and use with any bioreactor without protocol adjustments. Projects typically take 6-9 months with collaborative research planning for cell therapy developers seeking tailored activation reagents.
  • Drug Master File (DMF) for Synecta T1 Regulatory support offering that allows clinical-stage cell therapy developers to reference BlueWhale Bio's FDA-accepted Drug Master File for Synecta T1 in their new or amended IND submissions, supporting use of Synecta T1 CDNPs in clinical CAR-T manufacturing without requiring customers to compile and submit their own manufacturing CMC filings.
  • FDA Advanced Manufacturing Technology (AMT) Designation for Synecta Platform Regulatory designation service for the Synecta platform that signals FDA confidence in the scalability of the CDNP manufacturing approach, enables early FDA engagement on platform improvements, and supports customers pursuing commercial-scale cell therapy manufacturing.

Quantifiable outcome

  • Up to 30% of samples fail to reach target dose due to suboptimal activation
  • +2 more outcomes

Companies that use BlueWhale Bio

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

BlueWhale Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

BlueWhale Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AvantorcoreStrategic or Co-development Partner · 15 October 2025Strategic partnership to accelerate CAR-T manufacturing by scaling up production of BlueWhale's Synecta CDNP platform. The collaboration aims to reduce manufacturing time and costs while expanding patient access. Avantor brings bioprocessing and GMP-grade custom ancillary-reagent manufacturing capabilities to produce GMP-grade CDNP materials.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

BlueWhale Bio competitors and assessment

Company assessment

Direct peers

  • Miltenyi Biotec: Miltenyi Biotec is the dominant supplier of T-cell activation and expansion reagents (including T Cell TransAct nanomatrix) used in CAR-T manufacturing workflows globally. Direct competitor to BlueWhale's Synecta platform in the cell therapy activation reagent market.
  • Bio-Techne: Bio-Techne supplies GMP-grade cytokines (IL-2, IL-7, IL-15) and activation reagents widely used in CAR-T and other cell therapy manufacturing. Competes with the soluble-cytokine-free value proposition of Synecta T1.
  • CellGenix: CellGenix is a specialized supplier of GMP-manufactured raw materials and ancillary reagents for cell and gene therapy, including cytokines, media, and activation reagents. Closely comparable niche player focused on cell therapy manufacturing inputs.

Broad incumbents

  • Thermo Fisher Scientific (Gibco CTS): Thermo Fisher's Gibco CTS product line includes Dynabeads CD3/CD28 activation reagents and a broad portfolio of cell therapy manufacturing consumables and instruments. A large incumbent whose cell therapy franchise directly overlaps with BlueWhale's target market.
  • Cytiva: Cytiva (a Danaher company) supplies a broad portfolio of cell therapy bioprocessing tools, media, and instruments. Synergistic with BlueWhale's positioning - BlueWhale's lead investor Danaher also owns Cytiva - and represents both a partnership opportunity and a potential future competitive threat at the platform level.
  • Lonza Cell & Gene Technologies: Lonza is one of the world's largest cell and gene therapy CDMOs and also supplies process development tools and ancillary materials. A broad incumbent in the cell therapy manufacturing value chain that competes for ancillary reagent spend with cell therapy developers.
  • Charles River Laboratories: Charles River Laboratories operates a major cell and gene therapy CDMO business and supplies ancillary manufacturing materials. A scaled incumbent competing for the same customer wallet in cell therapy development and manufacturing services.

Emerging players

  • MaxCyte: MaxCyte provides electroporation-based cell engineering technology used in cell therapy manufacturing, including partnerships with major CAR-T developers. Adjacent technology provider in the cell therapy manufacturing workflow that competes for similar customer relationships.
  • Ori Biotech: Ori Biotech develops a fully closed, automated cell and gene therapy manufacturing platform. BlueWhale has co-hosted educational webinars with Ori, suggesting overlapping but not directly competing offerings in next-generation CAR-T manufacturing.
  • Kytopen: Kytopen is an MIT spinout developing continuous flow electroporation technology for cell engineering, including CAR-T manufacturing. BlueWhale announced a partnership with Kytopen in September 2025, indicating complementary rather than directly competing technology positions.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BlueWhale Bio social profiles

Digital presence

BlueWhale Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BlueWhale Bio leadership team

Management profile

Number of profiles

Profiles17 records

BlueWhale Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BlueWhale Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BlueWhale Bio

What does BlueWhale Bio do?

BlueWhale Bio manufactures and sells the Synecta™ platform of cell-derived nanoparticles (CDNPs) used to activate and expand T cells during CAR-T and other immune cell therapy manufacturing. The CDNPs are engineered vesicles produced from mammalian cell lines that present defined combinations of activation signals, co-stimulatory ligands, membrane-bound cytokines, and adhesion molecules to mimic natural immune cell stimulation, eliminating bead-removal steps and enabling 3-day manufacturing with Day 0 lentiviral transduction. Customers are cell therapy developers, biomanufacturers, and academic medical centers, supported through direct sales, an e-commerce storefront, and a strategic GMP manufacturing partnership with Avantor.

Is BlueWhale Bio a public or private company?

BlueWhale Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was BlueWhale Bio founded?

BlueWhale Bio was founded in 2023. It employs 11 to 50 people.

Where is BlueWhale Bio based?

BlueWhale Bio is headquartered in Philadelphia, United States, in the North America region.

How does BlueWhale Bio make money?

One revenue line is on record: synecta Product Sales.

Who are BlueWhale Bio's main competitors?

Direct peers on record are Miltenyi Biotec, Bio-Techne and CellGenix. Broad incumbents are Thermo Fisher Scientific (Gibco CTS), Cytiva, Lonza Cell & Gene Technologies and Charles River Laboratories. Emerging players are MaxCyte, Ori Biotech and Kytopen.

Does BlueWhale Bio have an API?

No public API is recorded for BlueWhale Bio.

What industry is BlueWhale Bio in?

BlueWhale Bio's product category is Cell Therapy Manufacturing Reagents. Its primary akta.pro industry code is HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables), with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooAvantor, BlueWhale Partner Bio to Accelerate CAR-T Cell Therapy ManufacturingAvantor announced a partnership with BlueWhale Bio on October 15 to accelerate CAR-T cell therapy manufacturing. The collaboration combines Avantor's bioprocessing capabilities with BlueWhale's Synecta platform, which aims to reduce cell expansion time and variability. Preclinical and clinical data suggest the technology can lead to earlier cell division and higher yields.YahooAvantor Partners With BlueWhale Bio to Advance CAR-T ManufacturingAvantor entered a strategic partnership with BlueWhale Bio to advance CAR-T cell therapy manufacturing, combining its bioprocessing expertise with BlueWhale's CDNP technology. The collaboration aims to reduce variability and shorten time-to-patient, with shares trading flat after the announcement. The partnership could strengthen Avantor's position in the high-growth cell therapy market.SecSEC FORM DBlueWhale Bio, Inc., a biotechnology company incorporated in Delaware in 2022 and based in Philadelphia, Pennsylvania, filed a Form D notice with the SEC on October 16, 2025, for an exempt offering of equity securities under Rule 506(b). The company is seeking to raise up to $15,000,000, of which $5,000,000 has already been sold to one investor, leaving $10,000,000 remaining. The offering is not intended to last more than one year, and no sales commissions or finder's fees were paid in connection with the transaction.PR NewswireAvantor® and BlueWhale Bio Partner to Accelerate CAR-T Manufacturing with Breakthrough Cell Activation and Expansion TechnologyAvantor, Inc. announced a strategic partnership with BlueWhale Bio to combine Avantor's bioprocessing and custom ancillary-reagent manufacturing capabilities with BlueWhale Bio's Synecta™ cell-derived nanoparticle platform for CAR-T therapy production. The collaboration aims to accelerate GMP-grade CDNP manufacturing scale-up to reduce expansion time, lower costs, and address the cell therapy sector's manufacturing bottlenecks including high cost, variability, and lengthy release cycles. BlueWhale Bio's Synecta™ T1 CDNPs are currently used in a Phase 1 clinical trial for a 3-day CAR-T manufacturing process, with preclinical and clinical data showing earlier cell division and higher cell yields.The Daily PennsylvanianPenn faculty biotech startup launches trial for advanced cancer immunotherapyA clinical trial for cancer immunotherapy, utilizing the Synecta platform, was launched by BlueWhale Bio, a biotech startup founded by professors from the Perelman School of Medicine. The trial aims to test the safety and feasibility of a new CAR T-cell therapy, huCART19-IL18, for treating CD19+ cancers. BlueWhale Bio has raised $18 million in seed financing to enhance cell therapy production and plans to expand its sales and marketing efforts in the coming years.PR NewswireKytopen Announces Collaboration with BlueWhale Bio to Revolutionize Cell Therapy ManufacturingKytopen and BlueWhale Bio announced a collaboration to develop a non-viral cell therapy manufacturing workflow. BlueWhale's Synecta CDNPs mimic T-cell priming, while Kytopen's Flowfect technology processes billions of cells in minutes. The partnership aims to reduce vein-to-vein times and lower costs for personalized cell therapies.PR NewswireBlueWhale Bio Announces First Patient Dosed in Clinical Trial Using Synecta™ T1 Cell-Derived Nanoparticles (CDNPs)BlueWhale Bio announced that the first patient has been dosed in a clinical trial at the University of Pennsylvania using the company's Synecta™ T1 cell-derived nanoparticles (CDNPs) for manufacturing huCART19-IL18 cells to treat hematologic cancers. The FDA accepted BlueWhale Bio's Drug Master File for Synecta T1 CDNPs, representing the first regulatory clearance of CDNPs for T-cell activation, with preclinical studies showing the product outperformed commercially available activation methods in reaching target dose levels faster and with greater consistency.FinSMEsBlueWhale Bio Raises $18M in FundingBlueWhale Bio, a cell and gene therapy manufacturing company spun out of the University of Pennsylvania, has raised $18 million in funding. The round was led by Danaher Ventures LLC, with participation from investors including Novalis LifeSciences and Marshall Wace. The company intends to use the capital to expand its operations and research and development capabilities.Silicon Valley JournalsBlueWhale Bio Secures $18 Million in Seed Financing Led by Danaher VenturesBlueWhale Bio, a company spun out of the University of Pennsylvania, has raised $18 million in seed financing, led by Danaher Ventures LLC. The funding aims to tackle significant bottlenecks in cell and gene therapy manufacturing, with expectations to enhance patient accessibility and reduce treatment costs. The company is eager to revolutionize the treatment paradigm in cell therapy, addressing current limitations in the field.